ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Tafamidis Meglumine Soft Capsules

Its studies are mostly in Amyloid Neuropathies, Familial, led by Qilu Pharmaceutical.

Furthest: phase 4, since Apr 8, 20251 company-led study, 1 open or runningNext primary completion: Jan 2028 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical11 open or runningphase 4since Apr 8, 2025Apr 8, 2025Jan 2028phase 4 · NCT06940336

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 8, 2025First study: phase 4 study in Amyloid Neuropathies, FamilialFirst studyNCT06940336 · 15 planned · China

Ahead

  1. Jan 2028Primary completion: phase 4 study in Amyloid Neuropathies, FamilialNCT06940336

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06940336Amyloid Neuropathies, Familial · China4RecruitingJan 202815

How it is read

Names in the registry

  • “Tafamidis Meglumine Soft Capsules”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.